HSA and Japan MHLW signed a Memorandum of Cooperation on 20 April 2026 in Tokyo establishing bilateral GMP-inspection reliance for medicines, cell, tissue and gene therapy products, and medical devices: arrangement is expected to remove three duplicative inspections per year and accelerate patient access to medicines by up to six months while preserving domestic safety standards. Layered above existing JSEPA 2002, 2010 HSA-MHLW-PMDA Information Exchange Memorandum, PIC/S, and ICMRA multilateral substrate.

The Health Sciences Authority of Singapore (HSA) and Japan's Ministry of Health, Labour and Welfare (MHLW) signed a Memorandum of Cooperation in Tokyo on 20 April 2026, enhancing bilateral cooperation in health-products regulation. The MOC was signed by the Chief Executive Officer of HSA and the Director-General of the Pharmaceutical Safety Bureau of MHLW; the Chief Executive of Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and the Councillor for Pharmaceutical Affairs at MHLW were also present at the signing. The HSA press release marking the development was issued on 21 April 2026.

The MOC's core scope is Good Manufacturing Practice (GMP) inspection reliance — mutual recognition of GMP certificates and inspection outcomes for pharmaceutical manufacturers in both countries. HSA quantifies the operational impact: the arrangement is expected to remove an average of three duplicative inspections per year and to improve patient access to medicines by up to six months. Both parties retain their domestic safety standards.

The MOC's product scope spans the full pharmaceutical and medical-device lifecycle — from clinical-trials review, through product reviews, registration and reliance, manufacturing, to post-market oversight. The eligible product classes include medicines, cell, tissue and gene therapy products, and medical devices. The cooperation also covers information exchange on cutting-edge health technologies and joint participation in international and regional regulatory programmes.

The RegLegBrief Specialist Panel considered the HSA press release alongside the Japan–Singapore Economic Partnership Agreement (JSEPA, 30 November 2002) — Singapore's first free-trade agreement with a major trading partner and Japan's first-ever FTA — which the press release identifies as the diplomatic substrate; the 2010 Memorandum on Information Exchange between HSA, MHLW and PMDA, identified as the immediate predecessor; HSA's Medical Device Registration overview page documenting the existing Immediate Registration Pathway (2018) under which Australia TGA, Health Canada, EU notified bodies, Japan PMDA / MHLW, and US FDA already operate as reference regulators; and the multilateral substrate within which the bilateral MOC operates — namely the Pharmaceutical Inspection Co-operation Scheme (PIC/S) (HSA chairs the Sub-Committee on Training; Japan PMDA chairs the Sub-Committee on Communication) and the International Coalition of Medicines Regulatory Authorities (ICMRA), in which HSA and PMDA both participate.

Read against the comparable jurisdiction cohort, the Specialist Panel finds that the MOC builds on a well-established international precedent. The European Union–Japan Mutual Recognition Agreement on conformity assessment (operational from 29 May 2004), expanded on 18 July 2018 to include sterile medicines, biological medicines including vaccines and immunologicals, and active pharmaceutical ingredients of any covered medicine, is the most direct architectural antecedent — same mutual GMP-certificate recognition structure, same removal of duplicative inspections, same patient-access acceleration rationale. The European Medicines Agency and PMDA jointly administer the EU-Japan MRA, with Japan's GMP inspections conducted by PMDA and the forty-seven prefectural inspectorates.

Read alongside this MOC, the APEC Regulatory Harmonization Steering Committee (APEC-RHSC) — chaired by the United States Food and Drug Administration with PMDA as vice-chair — provides the broader Asia-Pacific multilateral convergence context for pharmaceuticals and medical devices. Singapore HSA participates as an APEC RHSC contributing regulator. The MOC sits as a bilateral reinforcement layer above this regional substrate.

The MOC is also a sibling of HSA's parallel bilateral with Korea's Ministry of Food and Drug Safety: the joint Guiding Principles for Conducting Clinical Trial for Machine Learning-enabled Medical Devices, co-issued with Korea's MFDS and preserved at RegLegBrief citation RLB-SG-2026-00060 as Annex-04 of the MOH-HSA AI in Healthcare Guidelines Version 2.0. Singapore is methodically constructing a network of bilateral reliance and harmonisation arrangements with Asian and global regulators — Japan MHLW (April 2026), Korea MFDS (March 2026 GMLP), Australia TGA, Health Canada, EU notified bodies, and US FDA. The complete document set is listed in the document panel below.

The professional categories materially affected fall into three named groups. Pharmaceutical manufacturers registered with HSA under the Health Products Act 2007 (Act 14 of 2007) who operate manufacturing sites subject to GMP inspections — including holders of a manufacturer's licence and manufacturer's importer's licence under the Health Products (Therapeutic Products) Regulations 2016 — will see fewer duplicative inspections by the two regulators. Cell, tissue, and gene therapy product developers and medical-device manufacturers with cross-border product pipelines between Singapore and Japan should anticipate corresponding registration timeline acceleration. Regulatory affairs professionals advising on cross-border filings — including pharmacists registered with the Singapore Pharmacy Council under the Pharmacists Registration Act 2007 (Act 26 of 2007) employed in industry regulatory-affairs functions — should reassess registration sequencing to leverage the MOC's reliance pathway once operationalised.

The MOC is a non-binding cooperative arrangement; specific bilateral GMP-certificate recognition and inspection-reliance procedural details will follow in implementation guidance from HSA and PMDA. The agreement also gives both regulators a formal mechanism for coordinated post-market oversight, which over time may extend to bilateral pharmacovigilance signal sharing and coordinated regulatory action where cross-border safety concerns arise.

The MOC takes effect on its signing date of 20 April 2026, with operational implementation of GMP-inspection reliance expected to follow as the two regulators publish bilateral procedural guidance. Pharmaceutical manufacturers with active or planned manufacturing sites in either jurisdiction should monitor HSA and PMDA implementation announcements before recalibrating inspection cadence assumptions. This regulatory development is preserved and cited by RegLegBrief at reglegbrief.com/cite/RLB-SG-2026-00063.